TY - JOUR
T1 - Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries
AU - Sauer, Molly
AU - Vasudevan, Prarthana
AU - Nigam-Meghani, Ankita Nigam
AU - Luthra, Karuna
AU - Garcia, Cristina
AU - Knoll, Maria Deloria
AU - Privor-Dumm, Lois
N1 - Funding Information:
This work was supported by the World Health Organization (APW 201791058). The authors acknowledge the contributions of the U.S. Centers for Disease Control and Prevention ( CK14-1402 ), which provides financial support to the World Health Organization Initiative for Vaccine Research. The authors acknowledge the support and thoughtful review of Drs. Justin Ortiz and Martin Friede.
Funding Information:
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Lois Privor-Dumm has previously received funding from drug companies for investigator driven policy research (Pfizer, GSK and Merck). This does not alter our adherence to Vaccine policies on sharing data and materials. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.].
Publisher Copyright:
© 2021 The Authors
PY - 2021/3/12
Y1 - 2021/3/12
N2 - By 2050, the number of adults over 65 years of age will be double the under-5 population, and heavily concentrated in low- and middle-income countries. Population growth and increasing life expectancies call for effective healthy aging strategies inclusive of immunization to reduce the burden of vaccine-preventable diseases, improve quality of life, and mitigate antimicrobial resistance. Based on a review of available literature on the pneumococcal disease, influenza, and herpes zoster epidemiology and economic burden, and the health systems and policy barriers for adult immunization, we identified evidence gaps and considerations for prioritizing adult immunization. The body of evidence for adult immunization and the health and economic burden of adult disease is heavily concentrated in high-income countries. The few countries reporting adult immunization policies generally focus on high-risk groups. Despite robust child immunization programs in most countries, adult immunization programs and policies lag far behind and there is a general lack of appropriate delivery platforms. Global adult disease burden and economic costs are substantial but evidence from low- and middle-income countries is limited. There is a need for a strengthened evidence base and political commitment to drive a comprehensive, global technical consensus on adult immunization.
AB - By 2050, the number of adults over 65 years of age will be double the under-5 population, and heavily concentrated in low- and middle-income countries. Population growth and increasing life expectancies call for effective healthy aging strategies inclusive of immunization to reduce the burden of vaccine-preventable diseases, improve quality of life, and mitigate antimicrobial resistance. Based on a review of available literature on the pneumococcal disease, influenza, and herpes zoster epidemiology and economic burden, and the health systems and policy barriers for adult immunization, we identified evidence gaps and considerations for prioritizing adult immunization. The body of evidence for adult immunization and the health and economic burden of adult disease is heavily concentrated in high-income countries. The few countries reporting adult immunization policies generally focus on high-risk groups. Despite robust child immunization programs in most countries, adult immunization programs and policies lag far behind and there is a general lack of appropriate delivery platforms. Global adult disease burden and economic costs are substantial but evidence from low- and middle-income countries is limited. There is a need for a strengthened evidence base and political commitment to drive a comprehensive, global technical consensus on adult immunization.
KW - Adult immunization
KW - Herpes zoster vaccine
KW - Implementation
KW - Influenza vaccine
KW - Pneumococcal vaccine
KW - Policy
UR - http://www.scopus.com/inward/record.url?scp=85101102668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101102668&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.01.066
DO - 10.1016/j.vaccine.2021.01.066
M3 - Review article
C2 - 33618947
AN - SCOPUS:85101102668
VL - 39
SP - 1556
EP - 1564
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 11
ER -